Epigenetics and complex disease: from etiology to new therapeutics.

Epigenetics is a new development in complex non-Mendelian disease, which may not only uncover etiologic and pathogenic mechanisms but may also provide the basis for the development of medications that would target the primary epigenetic causes of such diseases. Such epigenetic drugs would be novel, potentially possessing substantially higher therapeutic potential and a much lower rate of adverse effects in comparison to current symptomatic treatments. A collection of epigenetic drugs already exist at various stages of development and, although their effectiveness has yet to be maximized, they show great promise in the treatment of cancer, psychiatric disorders, and other complex diseases. Here we present a review of the epigenetic theory of complex disease and an evaluation of current epigenetic therapies, as well as predictions of the future directions in this expanding field.

[1]  M. Bourin,et al.  The role of mood stabilisers in the treatment of the depressive facet of bipolar disorders , 2007, Neuroscience & Biobehavioral Reviews.

[2]  Mahasti Saghatchian,et al.  Molecular targets and cancer therapeutics. , 2004, Drug discovery today.

[3]  M. Szyf,et al.  Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. , 2007, Biochemical pharmacology.

[4]  E. Sausville,et al.  Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. , 2007, Blood.

[5]  M. Esteller Cancer epigenomics: DNA methylomes and histone-modification maps , 2007, Nature Reviews Genetics.

[6]  Jonathan Pevsner,et al.  FXYD1 is an MeCP2 target gene overexpressed in the brains of Rett syndrome patients and Mecp2-null mice. , 2007, Human molecular genetics.

[7]  J. LaSalle,et al.  15q11-13 GABAA receptor genes are normally biallelically expressed in brain yet are subject to epigenetic dysregulation in autism-spectrum disorders. , 2007, Human molecular genetics.

[8]  Yi Zhang,et al.  Regulation of histone methylation by demethylimination and demethylation , 2007, Nature Reviews Molecular Cell Biology.

[9]  D. Waggoner Mechanisms of disease: epigenesis. , 2007, Seminars in pediatric neurology.

[10]  E. Costa,et al.  Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder , 2007, Schizophrenia Research.

[11]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature reviews. Drug discovery.

[12]  M. Szyf,et al.  Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. , 2007, Carcinogenesis.

[13]  Dong Hoon Kim,et al.  Psammaplin A is a natural prodrug that inhibits class I histone deacetylase , 2007, Experimental & Molecular Medicine.

[14]  Karl Mechtler,et al.  Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. , 2007, Molecular cell.

[15]  T. Bijma,et al.  The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells , 2007, Leukemia.

[16]  E. Andres Houseman,et al.  Global DNA Methylation Level in Whole Blood as a Biomarker in Head and Neck Squamous Cell Carcinoma , 2007, Cancer Epidemiology Biomarkers & Prevention.

[17]  D. Qian,et al.  Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma , 2007, Molecular Cancer Therapeutics.

[18]  Minoru Yoshida,et al.  [Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[19]  M. Fang,et al.  Dietary polyphenols may affect DNA methylation. , 2007, The Journal of nutrition.

[20]  Ronald Breslow,et al.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug , 2007, Nature Biotechnology.

[21]  Chunlei Zhang,et al.  Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). , 2007, Blood.

[22]  Michael Rytting,et al.  Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. , 2006, Blood.

[23]  Yan Wu,et al.  Inhibition of Proliferation of Endometrial Stromal Cells by Trichostatin A, RU486, CDB-2914, N-Acetylcysteine, and ICI 182780 , 2006, Gynecologic and Obstetric Investigation.

[24]  Hui Shen,et al.  Assessment of genetic linkage and parent-of-origin effects on obesity. , 2006, The Journal of clinical endocrinology and metabolism.

[25]  K. Bélanger,et al.  Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115. , 2006, Annals of Oncology.

[26]  Tae Hoon Kim,et al.  Genome-wide analysis of protein-DNA interactions. , 2006, Annual review of genomics and human genetics.

[27]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[28]  B. Conley,et al.  Targeting epigenetic abnormalities with histone deacetylase inhibitors , 2006, Cancer.

[29]  P. Houghton,et al.  Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Zwiller,et al.  Fluoxetine and Cocaine Induce the Epigenetic Factors MeCP2 and MBD1 in Adult Rat Brain , 2006, Molecular Pharmacology.

[31]  A. Rosemurgy,et al.  Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  W. Stadler,et al.  A phase II study of depsipeptide in refractory metastatic renal cell cancer. , 2006, Clinical genitourinary cancer.

[33]  L. Poirier,et al.  Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats. , 2006, Carcinogenesis.

[34]  Peter Natesan Pushparaj,et al.  SHORT INTEFERING RNA (siRNA) AS A NOVEL THERAPEUTIC , 2006, Clinical and Experimental Pharmacology and Physiology.

[35]  A. Wagschal,et al.  Epigenetic deregulation of imprinting in congenital diseases of aberrant growth. , 2006, BioEssays : news and reviews in molecular, cellular and developmental biology.

[36]  E. Richards Inherited epigenetic variation — revisiting soft inheritance , 2006, Nature Reviews Genetics.

[37]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[38]  Kevin K. Yang,et al.  Apoptosis Signal-regulating Kinase 1 Is a Direct Target of E2F1 and Contributes to Histone Deacetylase Inhibitorinduced Apoptosis through Positive Feedback Regulation of E2F1 Apoptotic Activity* , 2006, Journal of Biological Chemistry.

[39]  E. Nestler,et al.  Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action , 2006, Nature Neuroscience.

[40]  Arturas Petronis,et al.  Complex disease, gender and epigenetics , 2006, Annals of medicine.

[41]  Peter A. Jones,et al.  Epigenetic therapy of cancer: past, present and future , 2006, Nature Reviews Drug Discovery.

[42]  R. Ficner,et al.  Crystal structure of a bacterial class 2 histone deacetylase homologue. , 2005, Journal of molecular biology.

[43]  C. Steidl,et al.  Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia , 2005, Annals of Hematology.

[44]  J. Cen,et al.  [Mechanism of differentiation and apoptosis in leukemia cells induced by tributyrin]. , 2005, Zhongguo shi yan xue ye xue za zhi.

[45]  M. Dokmanovic,et al.  Prospects: Histone deacetylase inhibitors , 2005, Journal of cellular biochemistry.

[46]  P. Hagerman,et al.  Recent advances in fragile X: a model for autism and neurodegeneration , 2005, Current opinion in psychiatry.

[47]  T. Spector,et al.  Epigenetic differences arise during the lifetime of monozygotic twins. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Emily Bernstein,et al.  RNA meets chromatin. , 2005, Genes & development.

[49]  Frank Lyko,et al.  Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. , 2005, Cancer research.

[50]  W. Lam,et al.  Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells , 2005, Nature Genetics.

[51]  E. Sausville,et al.  Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Alexander V. Lyubimov,et al.  Plasma Pharmacokinetics, Oral Bioavailability, and Interspecies Scaling of the DNA Methyltransferase Inhibitor, Zebularine , 2005, Clinical Cancer Research.

[53]  Joseph Biederman,et al.  The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies , 2005, Psychological Medicine.

[54]  D. Qian,et al.  Epigenetic Modulation of Retinoic Acid Receptor β2 by the Histone Deacetylase Inhibitor MS-275 in Human Renal Cell Carcinoma , 2005, Clinical Cancer Research.

[55]  A. Dueñas-González,et al.  A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes , 2005, BMC Cancer.

[56]  D. Reinberg,et al.  The key to development: interpreting the histone code? , 2005, Current opinion in genetics & development.

[57]  M. Fraga,et al.  Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer , 2005, Nature Genetics.

[58]  E Maestrini,et al.  Analysis of IMGSAC autism susceptibility loci: evidence for sex limited and parent of origin specific effects , 2005, Journal of Medical Genetics.

[59]  Manel Esteller,et al.  DNA methylation and cancer therapy: new developments and expectations , 2005, Current opinion in oncology.

[60]  M. Grever,et al.  A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. , 2004, Blood.

[61]  A. Ardizzoni,et al.  In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. , 2005, Oncology research.

[62]  L. Altucci,et al.  Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells , 2005, Nature Medicine.

[63]  P. Laird Cancer epigenetics. , 2005, Human molecular genetics.

[64]  S. Grant,et al.  The histone deacetylase inhibitor sodium butyrate induces breast cancer cell apoptosis through diverse cytotoxic actions including glutathione depletion and oxidative stress. , 2004, International journal of oncology.

[65]  Minoru Yoshida,et al.  Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones. , 2004, Bioorganic & medicinal chemistry letters.

[66]  Michael J Meaney,et al.  Epigenetic programming by maternal behavior , 2004, Nature Neuroscience.

[67]  Gangning Liang,et al.  Preferential response of cancer cells to zebularine. , 2004, Cancer cell.

[68]  A. Petronis The origin of schizophrenia: genetic thesis, epigenetic antithesis, and resolving synthesis , 2004, Biological Psychiatry.

[69]  C. Fuke,et al.  Age Related Changes in 5‐methylcytosine Content in Human Peripheral Leukocytes and Placentas: an HPLC‐based Study , 2004, Annals of human genetics.

[70]  J. Nemunaitis,et al.  Phase I Study of Oral CI-994 in Combination with Carboplatin and Paclitaxel in the Treatment of Patients with Advanced Solid Tumors , 2004, Cancer investigation.

[71]  K. Camphausen,et al.  Enhanced Radiation-Induced Cell Killing and Prolongation of γH2AX Foci Expression by the Histone Deacetylase Inhibitor MS-275 , 2004, Cancer Research.

[72]  A. Wozniak,et al.  Chronic Oral Administration of CI-994: A Phase I Study , 2004, Investigational New Drugs.

[73]  Jorge A. Almenara,et al.  Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. , 2003, Molecular cancer therapeutics.

[74]  P. Atadja,et al.  N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). , 2003, Journal of medicinal chemistry.

[75]  Robert A. Waterland,et al.  Transposable Elements: Targets for Early Nutritional Effects on Epigenetic Gene Regulation , 2003, Molecular and Cellular Biology.

[76]  J. Bennett,et al.  Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. , 2003, Molecular vision.

[77]  M. D'Esposito,et al.  Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia , 2003, The Lancet.

[78]  E. Eisenhauer,et al.  A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[79]  Carl O. Pabo,et al.  Drug discovery with engineered zinc-finger proteins , 2003, Nature Reviews Drug Discovery.

[80]  R. Jaenisch,et al.  Chromosomal Instability and Tumors Promoted by DNA Hypomethylation , 2003, Science.

[81]  R. Strausberg,et al.  From Knowing to Controlling: A Path from Genomics to Drugs Using Small Molecule Probes , 2003, Science.

[82]  Rosanna Weksberg,et al.  Beckwith-Wiedemann syndrome demonstrates a role for epigenetic control of normal development. , 2003, Human molecular genetics.

[83]  P. Laird Early detection: The power and the promise of DNA methylation markers , 2003, Nature Reviews Cancer.

[84]  Wei Ye,et al.  Inhibition of DNA methylation and reactivation of silenced genes by zebularine. , 2003, Journal of the National Cancer Institute.

[85]  Max Costa,et al.  Epigenetics and the Environment , 2003, Annals of the New York Academy of Sciences.

[86]  Kuang-Hung Cheng,et al.  Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code , 2003, Annals of the New York Academy of Sciences.

[87]  A. Bird,et al.  Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals , 2003, Nature Genetics.

[88]  F. McMahon,et al.  Additional, physically ordered markers increase linkage signal for bipolar disorder on chromosome 18q22 , 2003, Biological Psychiatry.

[89]  A. Paterson,et al.  Monozygotic twins exhibit numerous epigenetic differences: clues to twin discordance? , 2003, Schizophrenia bulletin.

[90]  H. Hoogsteden,et al.  Asthma remission: does it exist? , 2003, Current opinion in pulmonary medicine.

[91]  C. Sung,et al.  Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. , 2002, Cancer letters.

[92]  Lei Zhou,et al.  Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. , 2002, Journal of molecular biology.

[93]  M. Ehrlich,et al.  DNA methylation in cancer: too much, but also too little , 2002, Oncogene.

[94]  D. Fallin,et al.  Evidence for parent of origin effect in late-onset Alzheimer disease. , 2002, American journal of medical genetics.

[95]  G. Wolff,et al.  Maternal methyl supplements in mice affect epigenetic variation and DNA methylation of offspring. , 2002, The Journal of nutrition.

[96]  S. Baylin,et al.  Altered methylation patterns in cancer cell genomes: cause or consequence? , 2002, Cancer cell.

[97]  Albert Jeltsch,et al.  Beyond Watson and Crick: DNA Methylation and Molecular Enzymology of DNA Methyltransferases , 2002, Chembiochem : a European journal of chemical biology.

[98]  S. Bates,et al.  Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[99]  W. Wilson,et al.  Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. , 2001, Blood.

[100]  D. Bernhard,et al.  The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[101]  A. Petronis,et al.  Human morbid genetics revisited: relevance of epigenetics. , 2001, Trends in genetics : TIG.

[102]  M. Yoshida,et al.  Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[103]  S. Biade,et al.  Chemical agents that promote chromatin compaction radiosensitize tumour cells , 2001, International journal of radiation biology.

[104]  F. Demenais,et al.  Detection of Parent‐of‐Origin Effects for Atopy by Model‐Free and Model‐Based Linkage Analyses , 2001, Genetic epidemiology.

[105]  H. W. Lee,et al.  Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. , 2000, Cancer research.

[106]  J. Herman,et al.  DNA hypermethylation in tumorigenesis: epigenetics joins genetics. , 2000, Trends in genetics : TIG.

[107]  M. Lübbert,et al.  Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  P. Marks,et al.  Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.

[109]  H. Ostrer Sex-based differences in gene transmission and gene expression , 1999, Lupus.

[110]  Peter A. Jones,et al.  Cancer-epigenetics comes of age , 1999, Nature Genetics.

[111]  R. Kodell,et al.  Maternal epigenetics and methyl supplements affect agouti gene expression in Avy/a mice , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[112]  A. Riggs,et al.  Methylation dynamics, epigenetic fidelity and X chromosome structure. , 1998, Novartis Foundation symposium.

[113]  M. Seeman Psychopathology in women and men: focus on female hormones. , 1997, The American journal of psychiatry.

[114]  N. Mori,et al.  Anticipation and Imprinting in Schizophrenia , 1997, Biological Psychiatry.

[115]  S Henikoff,et al.  Exploring and explaining epigenetic effects. , 1997, Trends in genetics : TIG.

[116]  D M Schmatz,et al.  Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[117]  R A Rifkind,et al.  Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[118]  D. Barlow,et al.  Gametic Imprinting in Mammals , 1995, Science.

[119]  M. Yoshida,et al.  Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. , 1993, The Journal of biological chemistry.

[120]  D. Reiss,et al.  Genetics and psychiatry: an unheralded window on the environment. , 1991, American Journal of Psychiatry.

[121]  M. Azim Surani,et al.  Epigenetic control of transgene expression and imprinting by genotype-specific modifiers , 1990, Cell.

[122]  J. Hall,et al.  Genomic imprinting: review and relevance to human diseases. , 1990, American journal of human genetics.

[123]  M. Yoshida,et al.  Effects of trichostatins on differentiation of murine erythroleukemia cells. , 1987, Cancer research.

[124]  Peter A. Jones,et al.  Cellular differentiation, cytidine analogs and DNA methylation , 1980, Cell.